雷芬那新,CAS 登记号 864750-70-9,由济南圣和化工有限公司现货供应,可提供纯度 按批次COA提供(不公开发布) 的规格,下游主要用于有机化学品。支持样品与小批量试用,批量价格请联系我们获取,验收以批次 COA 为准。
有机化学品
每批随货提供 COA;可按需提供 MSDS 及技术文件。邮件注明产品名称与 CAS 号,一个工作日内回复报价。
本页已列出 雷芬那新 的 CAS 号:864750-70-9,可与随货 COA 核对。
常见纯度为 按批次COA提供(不公开发布),包装形式为 按订单/批次确认(不公开发布),特殊规格可在询价时说明。
主要涉及有机化学品。
来信 info@591daili.com 或 WhatsApp 联系,提供产品名称、CAS 号与数量,确认价格与交期后即可安排发货,验收以批次 COA 为准。
Revefenacin · CAS 864750-70-9 · C35H43N5O4. UNII G2AE2VE07O. Boiling Point: 777.5; Solubility: < 1 mg/ml; LogP: 3.22.
| CAS Registry Number | 864750-70-9 |
|---|---|
| PubChem CID | 11753673 |
| Molecular formula | C35H43N5O4 |
| IUPAC name | [1-[2-[[4-[(4-carbamoylpiperidin-1-yl)methyl]benzoyl]-methylamino]ethyl]piperidin-4-yl] N-(2-phenylphenyl)carbamate |
| UNII (FDA) | G2AE2VE07O |
| Molecular Weight | 597.7 |
|---|---|
| XLogP3 | 4.1 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 11 |
| Exact Mass | 597.33150487 |
| Monoisotopic Mass | 597.33150487 |
| Topological Polar Surface Area | 108 |
| Heavy Atom Count | 44 |
| Formal Charge | 0 |
| Boiling Point | 777.5 |
|---|---|
| Solubility | < 1 mg/ml |
| LogP | 3.22 |
| Reported hazard statements | H302 (100%), H312 (100%), H332 (100%) |
|---|
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
Revefenacin; 864750-70-9; TD-4208; Yupelri; GSK-1160724; revefenacina; revefenacine; GSK1160724; G2AE2VE07O; DTXSID701027775; revefenacinum; RefChem:57759; R03BB08; DTXCID801513351; Revefenacin [INN]; Revefenacin [WHO-DD]
CAS 864750-70-9; molecular formula C35H43N5O4; molecular weight — g/mol.
Revefenacin, 864750-70-9, TD-4208, Yupelri, GSK-1160724, revefenacina.
Hazard statements reported: H302, H312, H332.
Boiling Point: 777.5; Solubility: < 1 mg/ml; LogP: 3.22.
Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.